Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw

[1] Ruggiero SL(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update J Oral Maxillofac Surg. 72 1938-1956

[2] Dodson TB(2008)Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs J Am Dent Assoc 139 1674-1677

[3] Fantasia J(2003)Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg. 61 1115-1117

[4] Goodday R(2015)Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Lancet 386 1353-1361

[5] Aghaloo T(2015)Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution J Oral Maxillofac Surg. 73 1288-1295

[6] Mehrotra B(2011)Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis Int J Oral Maxillofac Surg. 40 277-284

[7] Edwards BJ(2010)Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice J Bone Miner Res. 25 1668-1679

[8] Hellstein JW(2013)IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws Clin Cancer Res. 19 3176-3188

[9] Jacobsen PL(1974)Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method Exp Hematol. 2 83-92

[10] Kaltman S(2003)HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells Exp Hematol. 31 890-896

[1] Ruggiero SL(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update J Oral Maxillofac Surg. 72 1938-1956

[2] Dodson TB(2008)Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs J Am Dent Assoc 139 1674-1677

[3] Fantasia J(2003)Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg. 61 1115-1117

[4] Goodday R(2015)Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Lancet 386 1353-1361

[5] Aghaloo T(2015)Surgical therapy for bisphosphonate-related osteonecrosis of the jaw: six-year experience of a single institution J Oral Maxillofac Surg. 73 1288-1295

[6] Mehrotra B(2011)Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis Int J Oral Maxillofac Surg. 40 277-284

[7] Edwards BJ(2010)Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice J Bone Miner Res. 25 1668-1679

[8] Hellstein JW(2013)IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws Clin Cancer Res. 19 3176-3188

[9] Jacobsen PL(1974)Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method Exp Hematol. 2 83-92

[10] Kaltman S(2003)HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells Exp Hematol. 31 890-896